Company research
ALPINE IMMUNE SCIENCES, INC.
CIK 1626199Updated Nov 16, 2026
Securities
Historical securities (1)
ALPN · NASDAQ · equity · closed May 20, 2024Name history
Nivalis Therapeutics, Inc. · through Jul 25, 2017N30 Pharmaceuticals, Inc. · through Nov 25, 2014
ALPN price & chart
Historical security
This listing closed May 20, 2024. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 379,852,000Source | 286,686,000Source | 255,900,000Source | 144,090,000Source |
| Property, Plant and Equipment, NetUSD | 1,484,000Source | 1,584,000Source | 1,716,000Source | 1,785,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 43,921,000Source | 13,376,000Source | 67,907,000Source | 34,959,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 167,000Source | 392,000Source | 25,000,000Source | — |
| Assets, CurrentUSD | 330,034,000Source | 240,993,000Source | 192,013,000Source | 107,101,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,455,000Source | 2,960,000Source | 4,710,000Source | 1,520,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,510,000Source | 8,219,000Source | 8,837,000Source | 9,401,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 51,911,000Source | 107,266,000Source | 134,997,000Source | 81,932,000Source |
| Stockholders’ equity: | ||||
| Retained Earnings (Accumulated Deficit)USD | -256,145,000Source | -223,961,000Source | -166,199,000Source | -115,866,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 397,000Source | -1,121,000Source | -273,000Source | 53,000Source |
| Stockholders' Equity Attributable to ParentUSD | 327,941,000Source | 179,420,000Source | 120,903,000Source | 62,158,000Source |
| Additional Paid in Capital, Common StockUSD | 583,629,000Source | 404,456,000Source | 287,345,000Source | 177,947,000Source |
| Liabilities and EquityUSD | 379,852,000Source | 286,686,000Source | 255,900,000Source | 144,090,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 41,980,000Source | 57,996,000Source | 69,778,000Source | 41,167,000Source |
| Operating Lease, Liability, CurrentUSD | 912,000Source | 756,000Source | 617,000Source | 655,000Source |
| Accounts Payable, CurrentUSD | 3,593,000Source | 4,286,000Source | 3,349,000Source | 582,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,002,000Source | 10,085,000Source | 11,009,000Source | 11,815,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 21,187,000Source | 14,003,000Source | 9,417,000Source | 5,777,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | — | — |
| Long-term Debt, Current MaturitiesUSD | 0Source | 3,380,000Source | 4,622,000Source | 2,526,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | 3,380,000Source | 7,602,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,630,000Source | 9,648,000Source | 6,240,000Source | 4,140,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -225,000Source | -24,602,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | 155,000Source | 46,000Source | -214,000Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -79,012,000Source | -43,754,000Source | -15,248,000Source | 30,084,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -55,559,000Source | -113,348,000Source | -52,480,000Source | -72,819,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 487,000Source | 412,000Source | 118,000Source | 802,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 165,122,000Source | 102,689,000Source | 100,764,000Source | 61,381,000Source |
| Repayments of Long-term DebtUSD | 3,425,000Source | 4,800,000Source | 2,400,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 30,559,000Source | -54,531,000Source | 32,948,000Source | 18,704,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 44,189,000Source | 13,630,000Source | 68,161,000Source | 35,213,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 66,000Source | 322,000Source | 554,000Source | 490,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,000Source | -118,000Source | -88,000Source | 58,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,630,000Source | 9,648,000Source | 6,240,000Source | 4,140,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 45,000Source | 178,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | 0Source | 0Source | 0Source |
| DepreciationUSD | 576,000Source | 597,000Source | 620,000Source | 578,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -11,000Source | -93,000Source | -4,000Source | -5,000Source |
| General and Administrative ExpenseUSD | 22,222,000Source | 17,968,000Source | 14,560,000Source | 10,899,000Source |
| Income Tax Expense (Benefit)USD | 103,000Source | 2,330,000Source | -87,000Source | -6,000Source |
| Investment Income, InterestUSD | 11,852,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -32,184,000Source | -57,762,000Source | -50,333,000Source | -27,940,000Source |
| Operating ExpensesUSD | 103,126,000Source | 88,211,000Source | 73,302,000Source | 38,084,000Source |
| Other Nonoperating Income (Expense)USD | 415,000Source | -97,000Source | -4,000Source | — |
| Proceeds from Issuance of Common StockUSD | 161,905,000Source | 106,716,000Source | 11,929,000Source | 56,258,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | 0Source | 0Source | 5,000,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 296,275,000Source | 154,048,000Source | 81,156,000Source | 29,311,000Source |
| Proceeds from Stock Options ExercisedUSD | 4,791,000Source | 773,000Source | 502,000Source | 123,000Source |
| Realized Investment Gains (Losses)USD | 33,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Total RevenueUSD | 58,876,000Source | 30,064,000Source | 23,443,000Source | 9,335,000Source |
| Operating Income (Loss)USD | -44,250,000Source | -58,147,000Source | -49,859,000Source | -28,749,000Source |
| Other Nonoperating Income (Expense)USD | 415,000Source | -97,000Source | -4,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -32,081,000Source | -55,432,000Source | -50,420,000Source | -27,946,000Source |
| Income Tax Expense (Benefit)USD | 103,000Source | 2,330,000Source | -87,000Source | -6,000Source |
| Net Income (Loss) Attributable to ParentUSD | -32,184,000Source | -57,762,000Source | -50,333,000Source | -27,940,000Source |
| Earnings Per Share, BasicUSD per share | -0.64Source | -1.73Source | -1.98Source | — |
| Earnings Per Share, DilutedUSD per share | -0.64Source | -1.73Source | -1.98Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 50,000,339Source | 33,435,280Source | 25,476,889Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 50,000,339Source | 33,435,280Source | 25,476,889Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | -51,000Source | 2,282,000Source | 129,000Source | -6,000Source |
| General and Administrative ExpenseUSD | 22,222,000Source | 17,968,000Source | 14,560,000Source | 10,899,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -32,450,000Source | -55,475,000Source | -48,932,000Source | -28,356,000Source |
| Interest ExpenseUSD | 98,000Source | 476,000Source | 816,000Source | 775,000Source |
| Investment Income, InterestUSD | 11,852,000Source | — | — | — |
| Operating ExpensesUSD | 103,126,000Source | 88,211,000Source | 73,302,000Source | 38,084,000Source |
| Realized Investment Gains (Losses)USD | 33,000Source | — | — | — |
| Research and Development ExpenseUSD | 80,904,000Source | 70,243,000Source | 58,742,000Source | 27,185,000Source |